- MindBio Therapeutics (CSE:MBIO), a psychedelic healthcare stock, is reporting that patients administered its take-home LSD treatment, MB22001, showed a 65 per cent reduction in depressive symptoms one month after ceasing treatment
- The company is following up the phase 2A result with an ongoing placebo-controlled phase 2B clinical trial
- MindBio Therapeutics is a biotech and biopharma company creating psychedelics-based treatments for mental health conditions
- MindBio stock has given back 69.23 per cent since inception in May 2023
MindBio Therapeutics (CSE:MBIO), a psychedelic healthcare stock, is reporting that patients administered its take-home LSD treatment, MB22001, showed a 65 per cent reduction in depressive symptoms one month after ceasing treatment.
The result is part of MindBio’s phase 2A clinical trial, which used the Montgomery Asberg Depression Rating Scale, a global standard for measuring the severity of depression, to demonstrate MB22001’s excellent safety, adherence and tolerance profile over 8 weeks of treatment.
Phase 2A follows an extensive phase 1 trial in 80 healthy individuals yielding positive safety and tolerance data, in addition to significant improvements in mood and sleep quality, adding to MB22001’s case as an effective psychedelics-based drug for treating depression and staking a claim in the almost US$20 billion global market.
A randomized, triple blind and placebo-controlled phase 2B trial began earlier this year, following a second phase 2B trial focused on cancer initiated in late 2023, both of which are fully funded and will run into 2025. A third trial focused on pre-menstrual syndrome and pre-menstrual dysphoric disorder received regulatory approval in April.
MindBio’s thesis is that sub-hallucinogenic microdosing is a safer, scalable and more effective method to administer psychedelic medicine compared to the standard of care, where patients are given large doses in a clinical setting that require 6-8 hours of therapeutic assistance.
Leadership insights
“We are delighted to discover that MB22001 has shown a sustained antidepressant response one month after cessation of treatment,” Justin Hanka, MindBio’s chief executive officer, said in a statement. “This is good news for our current dosing in phase 2B clinical trials underway and further supportive that we have developed a groundbreaking potential new treatment for depression. This data is another small step towards commercialization.”
About MindBio Therapeutics
MindBio is a biotech and biopharma company creating psychedelics-based treatments for mental health conditions. The company is conducting the world’s first take-home LSD microdosing human clinical trials.
MindBio stock (CSE:MBIO) last traded at C$0.04 per share. The stock has given back 69.23 per cent since inception in May 2023.
Join the discussion: Find out what everybody’s saying about this psychedelic stock’s potential treatment against depression on the MindBio Therapeutics Corp. Bullboard, and check out Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top photo, generated by AI: Adobe Stock.)
